Related Experiment Videos
The Cardiac Arrhythmia Suppression Trial: background, interim results and implications
The American Journal of Cardiology
|January 16, 1990
Summary
The Cardiac Arrhythmia Suppression Trial found that encainide and flecainide increased arrhythmic death by 3.6-fold in heart attack survivors, challenging previous assumptions about proarrhythmia risk.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- The Cardiac Arrhythmia Suppression Trial (CAST) investigated suppressing ventricular premature complexes (VPCs) in myocardial infarction survivors.
- Previous studies suggested a low risk of proarrhythmia in this patient group.
Purpose of the Study:
- To test if suppressing VPCs reduces arrhythmic death risk in post-myocardial infarction patients.
- To evaluate the proarrhythmic potential of encainide and flecainide in this population.
Main Methods:
- A randomized, placebo-controlled clinical trial design.
- Inclusion of patients surviving acute myocardial infarction with moderate arrhythmic death risk.
Main Results:
- Encainide and flecainide groups showed a 3.6-fold increase in arrhythmic death compared to placebo.
- The placebo group exhibited an unusually low arrhythmic death rate.
- A high proarrhythmic event rate was observed in the 725-patient CAST cohort over 10 months.
Conclusions:
- Encainide and flecainide demonstrated a significant proarrhythmic effect in CAST participants.
- These findings challenge traditional concepts of proarrhythmia, possibly due to population-specific mechanisms.
- Randomized trials are crucial for uncovering unexpected drug liabilities.